Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?

Sarigul Yildirim F., User U., SAYAN M., Oztoprak N.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.24, sa.3, ss.90-95, 2018 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.4274/vhd.2018.0006
  • Dergi Adı: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.90-95
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Objectives: Pegylated-interferon (Peg-IFN) alpha 2a/2b and nucleoside and/or nucleotide analogues (NAs) are currently the only two treatment approaches approved for the chronic hepatitis B (CHB). To date, few studies have compared Peg-IFN with NAs in the treatment of CHB. We aimed in this study to evaluate the effectiveness of Peg-IFN and potent NAs (entecavir and tenofovir disoproxil) and to compare cumulative virological and serological resnonses in Turkish CHB patients treated between 2006 and 2016.